Select all docs (Max 200)
Narrow Results:
Publication Year
- 2013 1
Medical Subject
- Adolescent 1
- Adult 1
- Aged 1
- Antitubercular Agents 1
- Child 1
- Child, Preschool 1
- Drug Resistance, Bacterial 1
- Female 1
- Humans 1
- Infant 1
- Male 1
- Middle Aged 1
- Multivariate Analysis 1
- Mycobacterium tuberculosis 1
- Pyrazinamide 1
- Risk Factors 1
- Tuberculosis, Multidrug-Resistant 1
- United States 1
- Young Adult 1
Personal Author
Resource Type General
Keywords
Pyrazinamide
Select all docs (Max 200)
1 Results
Refine Results
Refine Results:
- Adolescent (1)
- Adult (1)
- Aged (1)
- Antitubercular Agents (1)
- Child (1)
- Child, Preschool (1)
- Drug Resistance, Bacterial (1)
- Female (1)
- Humans (1)
- Infant (1)
- Male (1)
- Middle Aged (1)
- Multivariate Analysis (1)
- Mycobacterium tuberculosis (1)
- Pyrazinamide (1)
- Risk Factors (1)
- Tuberculosis, Multidrug-Resistant (1)
- United States (1)
- Young Adult (1)
- :Kurbatova, Ekaterina V. ;Cavanaugh, Joseph S.10 2013 | Clin Infect Dis. 57(8):1081-1093:IntroductionPyrazinamide (PZA) is essential in tuberculosis (TB) treatment. We describe the prevalence, trends and predictors of PZA resistance in Myc...
To see more results, try removing search filters or changing the search terms
Exit Notification/Disclaimer Policy
Links with this icon indicate that you are leaving the CDC website.
- The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
- Linking to a non-federal Website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
- You will be subject to the destination website's privacy policy when you follow the link.
- CDC is not responsible for Section 508 compliance (accessibility) on other federal or private websites.